recombin
vesicular
stomat
viru
vsv
wide
use
vaccin
platform
howev
capac
vsvbase
vaccin
induc
mucos
immun
fulli
investig
present
studi
recombin
vsv
express
coxsackieviru
major
immunogen
gener
immun
protect
elicit
evalu
demonstr
intranas
deliveri
induc
potent
antigenspecif
mucos
immun
respons
well
system
immun
respons
particularli
induct
polyfunct
cell
importantli
mice
immun
better
protect
viral
myocard
receiv
chitosanformul
dna
vaccin
increas
dendrit
cell
dc
matur
mesenter
lymph
node
mln
observ
mice
vaccin
could
potenti
mechan
protect
immun
respons
find
support
vsv
viral
deliveri
vector
induc
robust
mucos
immun
consid
vaccin
develop
viral
myocard
vmc
induc
viral
infect
often
progress
chronic
myocard
persist
myocardi
inflamm
patient
sever
cardiac
dysfunct
may
also
develop
dilat
cardiomyopathi
one
frequent
reason
heart
transplant
although
mani
differ
infecti
agent
attribut
caus
viral
myocard
enteroviru
coxsackieviru
consid
common
caus
heart
diseas
adult
children
date
mani
potenti
vaccin
prevent
acut
infect
myocard
test
anim
model
includ
inactiv
viru
vaccin
attenu
viru
vaccin
recombin
protein
vaccin
dna
vaccin
viruslik
particl
vlp
vaccin
intramuscular
immun
mice
dna
vaccin
report
induc
variabl
humor
cellular
immun
result
protect
mice
lethal
infect
although
studi
promis
effect
clinic
vaccin
current
avail
henc
still
urgent
need
develop
new
vaccin
protect
infect
previou
studi
demonstr
import
humor
cellular
immun
respons
protect
agammaglobulinem
individu
particularli
suscept
enceph
mice
lack
b
cell
develop
chronic
infect
remain
virem
least
month
viremia
allevi
adopt
transfer
b
cell
wildtyp
mice
report
also
highlight
import
cellular
immun
viral
myocard
comparison
mice
resist
chronic
myocard
abysnj
mice
suscept
chronic
myocard
found
failur
clear
viru
may
attribut
defect
dendrit
cell
dc
maturationactiv
mhc
class
antigen
process
neutral
interleukin
increas
cell
amelior
patholog
cardiac
chang
reduc
viral
replic
member
enterovirus
invad
host
gastrointestin
tract
thu
import
vaccin
produc
mucos
immun
site
viral
transmiss
block
initi
infect
well
induct
potent
system
immun
respons
multitud
vehicl
includ
http
elsevi
ltd
right
reserv
microparticl
liposom
attenu
pathogen
develop
altern
platform
mucos
deliveri
vesicular
stomat
viru
vsv
viral
vaccin
vector
shown
excel
vector
deliv
foreign
antigen
use
revers
genet
exogen
gene
insert
vsv
genom
recombin
vsv
recov
entir
infecti
cdna
clone
exogen
antigen
express
continu
vivo
recombin
virus
inocul
anim
thu
trigger
specif
immun
respons
recombin
vsv
success
develop
number
vaccin
candid
human
immunodefici
viru
sever
acut
respiratori
syndrom
viru
hepat
c
viru
hepat
b
viru
influenza
viru
papillomaviru
human
respiratori
syncyti
viru
poxviru
ebola
viru
marburg
viru
vsvbase
hiv
vaccin
candid
success
earli
studi
recent
move
clinic
studi
hiv
vaccin
design
develop
team
program
collect
studi
demonstr
great
potenti
vsvbase
vaccin
trigger
strong
immun
even
singl
immun
dose
spite
capac
vsvbase
vaccin
induc
mucos
immun
yet
fulli
character
previous
report
mucos
vaccin
dna
plasmid
encapsul
chitosan
particl
protect
mice
viral
myocard
moder
level
mucos
iga
cell
immun
respons
induc
intranas
immun
develop
effici
vaccin
present
studi
appli
vsv
viral
vector
mucos
deliveri
system
express
main
antigen
protein
evalu
potenti
vsvbase
vaccin
induc
antigenspecif
mucos
system
immun
viral
myocard
mous
model
code
region
nanci
strain
major
capsid
protein
amplifi
pcr
clone
gl
junction
pvsvxn
plasmid
recombin
vsv
contain
recov
previous
describ
sixweekold
male
balbc
mice
purchas
experiment
anim
center
chines
academi
scienc
shanghai
china
remain
pathogenfre
condit
hous
soochow
univers
school
medicin
anim
facil
anim
experi
perform
accord
guidelin
care
use
laboratori
anim
ministri
health
china
guidelin
laboratori
anim
ethic
commiss
soochow
univers
mice
lightli
anesthet
inject
pentobarbit
sodium
cavum
abdomini
mgkg
prior
immun
group
contain
mice
vsvgfp
immun
singl
dose
plaqueform
unit
pfu
virus
l
volum
intranas
administ
group
mice
receiv
pb
alon
use
control
chitosandna
immun
group
mice
mildli
intranas
immun
chitosan
encapsul
g
g
time
biweekli
detect
antibodi
respons
lymphocyt
prolifer
assay
ctl
activ
assay
measur
dendirt
cell
matur
et
al
describ
previous
data
given
mean
sd
statist
analysi
data
perform
twotail
independ
student
ttest
use
graphpad
prism
version
graphpad
softwar
incorpor
p
consid
statist
signific
full
detail
method
provid
supplement
materi
method
code
region
main
antigen
protein
amplifi
pcr
clone
plasmid
gl
junction
vsv
genom
xhoi
nhei
restrict
enzym
indic
fig
vsvgfp
recombin
viru
gener
control
recov
recombin
virus
cell
previous
report
recombin
virus
purifi
plaqu
assay
immunofluoresc
stain
indic
effici
express
cytoplasm
region
cell
fig
also
detect
expect
green
fluoresc
vsvgfp
infect
cell
western
blot
confirm
express
well
express
vsv
glycoprotein
vsvg
infect
cell
fig
result
demonstr
success
gener
recombin
viru
express
antigen
administr
vaccin
mucos
surfac
shown
elicit
adequ
local
immun
respons
administr
site
distant
mucos
site
well
system
immun
respons
thu
group
mice
intranas
immun
vsvgfp
pb
describ
section
monitor
weight
chang
immun
mice
assess
effect
viral
infect
previous
report
mice
inocul
pfu
either
vsvgfp
demonstr
sever
weight
loss
well
clinic
symptom
tremor
paralysi
circl
within
day
post
inocul
recoveri
note
thereaft
data
shown
meanwhil
weight
mice
immun
pb
steadili
increas
significantli
differ
vsvgfp
group
week
post
inocul
analyz
antibodi
respons
immun
mice
blood
sampl
collect
mous
serum
igg
antibodi
respons
determin
elisa
indic
time
point
shown
fig
mice
immun
singl
dose
exhibit
high
serum
igg
respons
compar
mice
immun
vsvgfp
peak
week
post
inocul
drop
follow
week
serum
igg
level
mice
receiv
gradual
increas
three
addit
boost
reach
peak
week
interestingli
although
trend
fecal
secretori
iga
siga
gener
similar
serum
igg
product
faster
higher
immun
mice
fig
result
indic
intranas
immun
effici
induc
mucos
system
antibodi
respons
next
investig
cell
immun
respons
spleen
mesenter
lymph
node
mln
induc
immun
shown
fig
compar
mice
given
pb
vsvgfp
mice
immun
display
signific
increas
specif
cell
prolifer
spleen
mln
measur
brdu
assay
p
prolifer
level
even
higher
mice
immun
p
elispot
analysi
indic
mice
immun
develop
cell
spleen
specif
cytokinesecret
lymphocyt
quantifi
elispot
assay
respons
peptid
inactiv
h
c
ctl
activ
splenic
mesenter
cell
evalu
lactat
dehydrogenas
assay
use
stabletransfect
autolog
cell
target
cell
effectortarget
cell
ratio
result
repres
mean
sd
n
three
separ
experi
p
p
p
mln
frequenc
reach
spotform
cell
sfc
cell
respect
fig
p
mice
immun
produc
modest
amount
secret
cell
compar
control
group
agreement
elispot
data
strongest
cytotox
respons
also
detect
splenic
mesenter
lymphocyt
deriv
mice
immun
e
ratio
fig
taken
togeth
data
indic
addit
previous
report
vsvinduc
specif
system
cell
immun
respons
viral
pathogen
vsvbase
vaccin
also
induc
strong
mucos
antigenspecif
cell
immun
respons
determin
immun
protect
effect
week
final
dna
vaccin
immun
group
mice
infect
lethal
dose
ld
induc
acut
myocard
seven
day
postvir
infect
mice
group
vaccin
pb
vsvgfp
suffer
loss
bodi
weight
approxim
total
weight
fig
indic
develop
myocard
mice
detect
serum
creatin
kinas
ck
ckmb
activ
reflect
amount
cardiac
damag
immun
significantli
reduc
serum
ck
ckmb
activ
fig
c
exampl
ckmb
immun
group
iul
iul
vsvgfp
immun
group
addit
viral
titer
heart
tissu
immun
group
least
lower
vsvgfp
immun
group
fig
histolog
analysi
hematoxylin
eosin
stain
heart
section
show
larg
amount
myocyt
necrosi
immuneinfiltr
control
pb
vsvgfp
immun
group
tini
amount
inflamm
seen
immun
group
suggest
vaccin
prevent
develop
myocard
fig
similar
result
also
observ
hestain
pancrea
section
fig
vivo
ventricular
systol
function
measur
fraction
shorten
fs
eject
fraction
ef
use
valu
present
mean
sd
n
group
p
c
surviv
rate
mice
observ
day
follow
infect
individu
experi
conduct
three
time
mice
per
group
one
repres
data
shown
echocardiographi
assay
fig
left
ventricular
fs
lvf
immun
mice
lower
compar
immun
group
left
ventricular
ef
lvef
calcul
lower
immun
mice
compar
immun
group
fig
indic
vivo
ventricular
function
infect
improv
prior
immun
evalu
protect
abil
vaccin
candid
mice
challeng
ld
week
final
dna
immun
mockimmun
mice
succumb
sever
ill
die
within
day
immun
mice
immun
mice
surviv
day
sign
ill
fig
indic
nasal
immun
provid
protect
myocard
mln
b
frequenc
cell
produc
alon
analyz
stimul
h
c
frequenc
cell
express
two
three
analyz
proport
total
tripl
doubl
singl
posit
produc
cell
shown
pie
chart
result
express
mean
sd
n
three
independ
experi
p
p
dc
play
import
role
induct
adapt
immun
respons
examin
matur
mln
dc
immun
mice
use
flow
cytometri
two
week
final
immun
mln
cell
isol
stain
matur
maker
mhcii
togeth
characterist
marker
myeloidderiv
dc
dc
fulli
matur
vsvgfp
pb
immun
group
intranas
immun
mildli
promot
dc
matur
compar
level
matur
seen
immun
group
cell
surfac
express
mhcii
molecul
effici
upregul
fig
p
explor
consequ
dc
matur
next
measur
develop
polyfunct
cell
previou
report
shown
cell
multipl
effector
function
concomit
product
function
superior
singl
cytokineproduc
counterpart
clearanc
viral
pathogen
therefor
evalu
phenotyp
proport
polyfunct
cell
immun
mice
use
intracellular
cytokin
stain
multipl
cell
popul
could
delin
base
express
popul
first
gate
express
level
analyz
singleposit
cell
express
significantli
increas
immun
group
upon
peptid
stimul
significantli
higher
immun
group
cell
express
cytokin
bare
detect
control
immun
group
vsvgfp
pb
fig
p
assess
whether
cell
produc
one
cytokin
next
examin
coexpress
pattern
analysi
doubleposit
cell
reveal
proport
cell
lowest
immun
group
group
doubleposit
cell
abund
reach
immun
group
immun
group
percentag
tripleposit
polyfunct
cell
higher
doubleposit
cell
immun
group
immun
group
similar
level
express
seen
cell
fig
analysi
proport
singl
doubl
tripleposit
cell
immun
group
indic
immun
enhanc
magnitud
polyfunct
cell
detect
increas
doubl
tripleposit
popul
fig
present
studi
gener
vsvbase
vaccin
encod
major
antigen
protein
although
vsvbase
vector
wide
use
vaccin
platform
studi
character
capac
vsvbase
vaccin
induc
potent
mucos
immun
compar
antigenspecif
mucos
immun
elicit
intranas
administr
vaccin
chitosanbas
mucos
vaccin
singledos
intranas
deliveri
mice
exhibit
significantli
higher
level
mucos
system
immun
respons
mice
vaccin
improv
multipl
aspect
immun
one
import
virtu
mucos
vaccin
peak
level
antigenspecif
fecal
siga
group
similar
induct
antigenspecif
siga
immun
group
much
faster
immun
group
sinc
antigen
use
deliveri
system
studi
result
demonstr
vsvbase
vector
potent
induc
mucos
immun
chitosanbas
deliveri
system
increas
protect
viral
myocard
immun
mice
may
result
elev
humor
respons
well
cellular
immun
compar
oral
deliveri
simpl
altern
way
induc
mucos
immun
et
al
found
vsvbase
vaccin
human
noroviru
administr
combin
intranas
oral
deliveri
could
induc
antigenspecif
iga
gastrointestin
tract
vagina
base
success
oral
deliveri
would
like
worthwhil
investig
capac
vaccin
induc
mucos
system
immun
oral
deliveri
alon
combin
intranas
deliveri
sever
featur
make
vsv
ideal
vaccin
deliveri
mechan
first
vsv
induc
strong
mucos
immun
intranas
oral
immun
gastrointestin
tract
main
rout
invad
host
critic
induc
mucos
immun
respons
block
viru
infect
initi
stage
primari
site
second
viru
vsv
induc
strong
cellular
immun
compens
impair
cellular
immun
infect
kembal
et
al
found
infect
rapidli
induc
phenotyp
chang
convent
dc
markedli
impair
specif
cell
antigen
present
mhci
pathway
vivo
third
vsv
revers
genet
system
well
character
easi
manipul
high
titer
recombin
vsv
achiev
propag
viru
mammalian
cell
line
approv
vaccin
product
compar
potenti
vaccin
platform
baculoviru
vsv
system
faster
less
expens
final
vsv
vaccin
administ
needlefre
especi
valuabl
peopl
live
rural
region
short
health
care
polyfunct
cell
induc
immun
import
compon
robust
immun
respons
induc
vaccin
numer
studi
shown
qualiti
rather
level
cell
respons
crucial
determin
outcom
variou
infect
hcv
report
resolut
obtain
earli
interferon
therapi
correl
develop
polyfunct
specif
cell
vaccin
could
induc
polyfunct
cell
tripleposit
cell
immun
result
strike
increas
popul
addit
vaccin
induc
doubleposit
cell
base
previou
studi
specul
polyfunct
cell
could
establish
longlast
immunolog
memori
like
give
rise
strong
robust
secondari
respons
upon
challeng
dc
play
central
role
prime
immun
respons
therefor
interest
vaccin
capac
immunolog
paradigm
hold
dc
captur
antigen
inflammatori
signal
trigger
matur
migrat
drain
lymph
node
initi
antigenspecif
immun
respons
viral
vector
recombin
adenoviru
effici
infect
caus
matur
dc
vivo
induc
optim
vaccin
respons
previous
describ
vitro
bmdc
observ
vsv
infect
significantli
improv
matur
mln
dc
upregul
differ
molecul
week
postfin
immun
one
reason
might
stimul
caus
vsv
infect
stronger
last
longer
caus
chitosanincorpor
dna
site
immun
increas
matur
mln
dc
mice
like
result
sustain
migrat
activ
peripher
dc
inocul
site
addit
experi
ongo
address
hypothesi
studi
character
potenc
vsvbase
vaccin
vector
induct
mucos
immun
vaccin
promot
mucos
dc
matur
enhanc
antigenspecif
mucos
immun
well
system
immun
could
allevi
viral
myocard
studi
might
also
provid
insight
import
mucos
immun
develop
vsvbase
vaccin
